Developer docs
API playgroundTry for free, no card

Search company profiles

Day Zero Diagnostics

Full company profile

uuid0000h86

Namestring
Day Zero Diagnostics
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Day Zero Diagnostics is a Boston-based infectious disease diagnostics company founded in 2016 that combines whole genome sequencing with machine learning to identify bacterial and fungal pathogens and predict antimicrobial susceptibility directly from patient samples. The company's core offering is a rapid diagnostic system designed to deliver pathogen identification and antibiotic resistance profiles within approximately 8 hours, compared to multiple days for conventional culture-based methods, addressing a critical bottleneck in the treatment of serious infections and the global antimicrobial resistance crisis. Supporting products include the proprietary Blood2Bac™ sample preparation protocol for extracting microbial DNA from blood, and the epiXact® FMT pharmacovigilance assay for detecting pathogens in fecal microbiota transplant samples used in clinical trials and infection control.

The company's technology stack pairs a novel wet-lab sample preparation method with AI-driven analysis of sequencing data, and is being developed for hospital healthcare systems treating patients with suspected bloodstream infections and antimicrobial-resistant pathogens. As of September 2023, Day Zero Diagnostics had raised over $49 million in venture capital plus more than $18 million in non-dilutive funding (CARB-X and NIH), with strategic investors including BD, Sands Capital, Panacea Venture, and Hongkou Capital. The company employs 51–100 people, is privately held, and operates from a single headquarters location in Massachusetts.

The business model is currently pre-commercial: no revenue, pricing, or named customers are publicly disclosed, and the lead Rapid Diagnostic System is still in development toward FDA clearance. Capital raised to date is being deployed to improve the Blood2Bac™ protocol, accelerate the diagnostic system prototype, and fund the epiXact® FMT assay. GTM motion and revenue mechanics are not yet defined in publicly available sources, though the strategic investment from BD signals an eventual go-to-market path likely routed through hospital and clinical laboratory channels serving patients with serious infections.

Short descriptiontext

Day Zero Diagnostics is a Boston-based infectious disease diagnostics company developing genome sequencing and AI-powered systems to identify pathogens and predict antimicrobial resistance within 8 hours for hospitalized patients with serious infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infectious disease diagnostics, antimicrobial resistance testing, genomic pathogen identification, rapid blood culture diagnostics, clinical laboratory services
Industry4 codes
PRIMARYHLAAALAG
Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAKAGAA
General Infectious Disease
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Infectious Disease Diagnostics
No data
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1epiXact FMT
Description

Pharmacovigilance assay for fecal microbiota transplant safety using high-resolution genomic analysis pipeline to detect pathogens in complex samples

biospace.com
+1 more record
Core offering1 text field

Day Zero Diagnostics is an infectious disease diagnostics company that combines whole-genome sequencing with artificial intelligence and machine learning to identify bacterial pathogens and predict antimicrobial resistance profiles directly from clinical patient samples. Its Blood2Bac™ sample preparation protocol and Rapid Diagnostic System aim to deliver species-level identification and antibiotic susceptibility information in approximately 8 hours, materially faster than traditional culture-based workflows that can take several days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Pathogen and resistance profile identification within 8 hours, significantly faster than traditional methods
+1 more record
Product overview1 text field

Day Zero Diagnostics is developing a suite of genome sequencing-based diagnostic products centered around rapid pathogen identification and antimicrobial susceptibility testing. The core offering is a diagnostic system that uses whole genome sequencing combined with machine learning to identify bacterial and fungal pathogens and predict antibiotic resistance within 8 hours. Supporting products include the Blood2Bac™ sample preparation protocol for concentrating microbial DNA from blood, and the epiXact® FMT assay for fecal microbiota transplant safety monitoring. The company targets healthcare facilities dealing with infectious diseases and antimicrobial resistance.

Product and service3 records
1Blood2Bac™ Sample Preparation Protocol
CategoryInfectious Disease Diagnostics
Description

A proprietary sample preparation protocol that processes positive blood cultures to enable downstream whole-genome sequencing and machine-learning-based pathogen identification and antimicrobial resistance prediction for hospital clinical laboratories.

2Rapid Diagnostic System
CategoryInfectious Disease Diagnostics
Description

An integrated diagnostic platform combining proprietary sample preparation, whole-genome sequencing, and AI/machine-learning interpretation to deliver species identification and antimicrobial resistance profiles for bloodstream infections, designed for hospital healthcare systems and clinical laboratories.

3epiXact® FMT Pharmacovigilance Assay
CategoryMicrobiome Pharmacovigilance
Description

A pharmacovigilance assay service that uses the company's sequencing and bioinformatics capabilities to support safety and quality monitoring for fecal microbiota transplantation programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

T2 Biosystems develops rapid molecular diagnostics for sepsis and bloodstream infections directly from whole blood, targeting the same clinical use case (early pathogen ID) that Day Zero's sequencing-based system is designed to address.

TypeDirect peer
Description

Accelerate Diagnostics offers rapid pathogen identification and antimicrobial susceptibility testing directly from positive blood cultures, competing head-to-head with Day Zero's 8-hour ID/AST value proposition for hospitalized infection cases.

TypeBroad incumbent
Description

Global microbiology leader with BIOFIRE Blood Culture Identification panels, VITEK MS, and broad hospital diagnostics — overlapping directly with Day Zero's ID/AST workflow in clinical microbiology.

TypeBroad incumbent
Description

Major diagnostics and medical technology incumbent with BD MAX molecular systems and a broad microbiology portfolio; also a strategic investor in Day Zero, illustrating the overlap in target customers and applications.

TypeBroad incumbent
Description

Cepheid's GeneXpert platform is a dominant rapid molecular diagnostics system in hospitals, with sepsis and infection-related cartridges that compete for the same clinical decision points Day Zero targets.

TypeDirect peer
Description

BioFire's syndromic FilmArray panels (including the Blood Culture Identification panel) deliver same-day pathogen ID from positive blood cultures, making it the most direct commercial substitute for Day Zero's rapid ID/AST test.

TypeBroad incumbent
Description

QIAGEN provides sample-prep technologies and molecular diagnostic assays for infectious disease, overlapping with Day Zero's Blood2Bac™ sample-prep innovation and PCR-based ID workflows used in hospital labs.

TypeBroad incumbent
Description

Hologic's Panther / Panther Fusion systems and broad women's health and infectious disease molecular menu compete in the hospital molecular diagnostics space Day Zero is targeting.

TypeBroad incumbent
Description

Roche offers cobas molecular systems and a broad infectious disease and sepsis test menu in hospital labs, representing a large incumbent competitor in the same clinical workflow Day Zero aims to disrupt.

TypeEmerging player
Description

Illumina is the dominant DNA sequencing platform provider and has been expanding into clinical infectious disease applications, making it both a potential technology supplier and adjacent emerging competitor to Day Zero's sequencing-based diagnostic approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Day Zero Diagnostics

Infectious Disease Diagnosticsdayzerodiagnostics.com

Day Zero Diagnostics is a Boston-based infectious disease diagnostics company developing genome sequencing and AI-powered systems to identify pathogens and predict antimicrobial resistance within 8 hours for hospitalized patients with serious infections.

What Day Zero Diagnostics does

Day Zero Diagnostics is a Boston-based infectious disease diagnostics company founded in 2016 that combines whole genome sequencing with machine learning to identify bacterial and fungal pathogens and predict antimicrobial susceptibility directly from patient samples. The company's core offering is a rapid diagnostic system designed to deliver pathogen identification and antibiotic resistance profiles within approximately 8 hours, compared to multiple days for conventional culture-based methods, addressing a critical bottleneck in the treatment of serious infections and the global antimicrobial resistance crisis. Supporting products include the proprietary Blood2Bac™ sample preparation protocol for extracting microbial DNA from blood, and the epiXact® FMT pharmacovigilance assay for detecting pathogens in fecal microbiota transplant samples used in clinical trials and infection control.

The company's technology stack pairs a novel wet-lab sample preparation method with AI-driven analysis of sequencing data, and is being developed for hospital healthcare systems treating patients with suspected bloodstream infections and antimicrobial-resistant pathogens. As of September 2023, Day Zero Diagnostics had raised over $49 million in venture capital plus more than $18 million in non-dilutive funding (CARB-X and NIH), with strategic investors including BD, Sands Capital, Panacea Venture, and Hongkou Capital. The company employs 51–100 people, is privately held, and operates from a single headquarters location in Massachusetts.

The business model is currently pre-commercial: no revenue, pricing, or named customers are publicly disclosed, and the lead Rapid Diagnostic System is still in development toward FDA clearance. Capital raised to date is being deployed to improve the Blood2Bac™ protocol, accelerate the diagnostic system prototype, and fund the epiXact® FMT assay. GTM motion and revenue mechanics are not yet defined in publicly available sources, though the strategic investment from BD signals an eventual go-to-market path likely routed through hospital and clinical laboratory channels serving patients with serious infections.

Day Zero Diagnostics firmographics

Firmographics
Name
Day Zero Diagnostics
Website
https://dayzerodiagnostics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Day Zero Diagnostics is a Boston-based infectious disease diagnostics company developing genome sequencing and AI-powered systems to identify pathogens and predict antimicrobial resistance within 8 hours for hospitalized patients with serious infections.
Ownership category
akta.pro rank

Day Zero Diagnostics industry classification

Industry
Product category
Infectious Disease Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAG
Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAKAGAA
General Infectious Disease

Keywords

  • Infectious disease diagnostics
  • Antimicrobial resistance testing
  • Genomic pathogen identification
  • Rapid blood culture diagnostics
  • Clinical laboratory services

Where Day Zero Diagnostics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Day Zero Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Day Zero Diagnostics product offering

Product offering

Core offering

Day Zero Diagnostics is an infectious disease diagnostics company that combines whole-genome sequencing with artificial intelligence and machine learning to identify bacterial pathogens and predict antimicrobial resistance profiles directly from clinical patient samples. Its Blood2Bac™ sample preparation protocol and Rapid Diagnostic System aim to deliver species-level identification and antibiotic susceptibility information in approximately 8 hours, materially faster than traditional culture-based workflows that can take several days.

Product overview

Day Zero Diagnostics is developing a suite of genome sequencing-based diagnostic products centered around rapid pathogen identification and antimicrobial susceptibility testing. The core offering is a diagnostic system that uses whole genome sequencing combined with machine learning to identify bacterial and fungal pathogens and predict antibiotic resistance within 8 hours. Supporting products include the Blood2Bac™ sample preparation protocol for concentrating microbial DNA from blood, and the epiXact® FMT assay for fecal microbiota transplant safety monitoring. The company targets healthcare facilities dealing with infectious diseases and antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Brands

  • epiXact FMT: Pharmacovigilance assay for fecal microbiota transplant safety using high-resolution genomic analysis pipeline to detect pathogens in complex samples
  • Blood2Bac

Products and services

  • Blood2Bac™ Sample Preparation Protocol A proprietary sample preparation protocol that processes positive blood cultures to enable downstream whole-genome sequencing and machine-learning-based pathogen identification and antimicrobial resistance prediction for hospital clinical laboratories.
  • Rapid Diagnostic System An integrated diagnostic platform combining proprietary sample preparation, whole-genome sequencing, and AI/machine-learning interpretation to deliver species identification and antimicrobial resistance profiles for bloodstream infections, designed for hospital healthcare systems and clinical laboratories.
  • epiXact® FMT Pharmacovigilance Assay A pharmacovigilance assay service that uses the company's sequencing and bioinformatics capabilities to support safety and quality monitoring for fecal microbiota transplantation programs.

Quantifiable outcome

  • Pathogen and resistance profile identification within 8 hours, significantly faster than traditional methods
  • +1 more outcomes

Companies that use Day Zero Diagnostics

Customer profile

Segments1 record

Ideal customer profiles2 records

Day Zero Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Day Zero Diagnostics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Day Zero Diagnostics competitors and assessment

Company assessment

Direct peers

  • T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and bloodstream infections directly from whole blood, targeting the same clinical use case (early pathogen ID) that Day Zero's sequencing-based system is designed to address.
  • Accelerate Diagnostics: Accelerate Diagnostics offers rapid pathogen identification and antimicrobial susceptibility testing directly from positive blood cultures, competing head-to-head with Day Zero's 8-hour ID/AST value proposition for hospitalized infection cases.
  • bioMérieux BioFire Diagnostics: BioFire's syndromic FilmArray panels (including the Blood Culture Identification panel) deliver same-day pathogen ID from positive blood cultures, making it the most direct commercial substitute for Day Zero's rapid ID/AST test.

Broad incumbents

  • bioMérieux: Global microbiology leader with BIOFIRE Blood Culture Identification panels, VITEK MS, and broad hospital diagnostics — overlapping directly with Day Zero's ID/AST workflow in clinical microbiology.
  • Becton, Dickinson and Company (BD): Major diagnostics and medical technology incumbent with BD MAX molecular systems and a broad microbiology portfolio; also a strategic investor in Day Zero, illustrating the overlap in target customers and applications.
  • Cepheid (Danaher): Cepheid's GeneXpert platform is a dominant rapid molecular diagnostics system in hospitals, with sepsis and infection-related cartridges that compete for the same clinical decision points Day Zero targets.
  • QIAGEN: QIAGEN provides sample-prep technologies and molecular diagnostic assays for infectious disease, overlapping with Day Zero's Blood2Bac™ sample-prep innovation and PCR-based ID workflows used in hospital labs.
  • Hologic: Hologic's Panther / Panther Fusion systems and broad women's health and infectious disease molecular menu compete in the hospital molecular diagnostics space Day Zero is targeting.
  • Roche Diagnostics: Roche offers cobas molecular systems and a broad infectious disease and sepsis test menu in hospital labs, representing a large incumbent competitor in the same clinical workflow Day Zero aims to disrupt.

Emerging players

  • Illumina: Illumina is the dominant DNA sequencing platform provider and has been expanding into clinical infectious disease applications, making it both a potential technology supplier and adjacent emerging competitor to Day Zero's sequencing-based diagnostic approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Day Zero Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Day Zero Diagnostics leadership team

Management profile

Number of profiles

Profiles6 records

Day Zero Diagnostics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Day Zero Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Day Zero Diagnostics

What does Day Zero Diagnostics do?

Day Zero Diagnostics is an infectious disease diagnostics company that combines whole-genome sequencing with artificial intelligence and machine learning to identify bacterial pathogens and predict antimicrobial resistance profiles directly from clinical patient samples. Its Blood2Bac™ sample preparation protocol and Rapid Diagnostic System aim to deliver species-level identification and antibiotic susceptibility information in approximately 8 hours, materially faster than traditional culture-based workflows that can take several days.

Is Day Zero Diagnostics a public or private company?

Day Zero Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Day Zero Diagnostics founded?

Day Zero Diagnostics was founded in 2016. It employs 51 to 100 people.

Where is Day Zero Diagnostics based?

Day Zero Diagnostics is headquartered in Boston, United States, in the North America region.

Who are Day Zero Diagnostics's main competitors?

Direct peers on record are T2 Biosystems, Accelerate Diagnostics and bioMérieux BioFire Diagnostics. Broad incumbents are bioMérieux, Becton, Dickinson and Company (BD), Cepheid (Danaher), QIAGEN, Hologic and Roche Diagnostics. Illumina is listed as an emerging player.

Does Day Zero Diagnostics have an API?

No public API is recorded for Day Zero Diagnostics.

What industry is Day Zero Diagnostics in?

Day Zero Diagnostics's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAAALAG, Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow), with a secondary code of HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™The sepsis diagnostics market is projected to grow from $0.83 billion in 2026 to $1.22 billion by 2031, a 7.9% CAGR. North America held the largest regional share at 43.2% in 2025, and assays & reagent kits led the product segment. Growth is driven by rising sepsis incidence and demand for rapid diagnostics.PharmiWeb.comMolecular Infectious Disease Testing Market: Growth, Innovations, and OpportunitiesThe global molecular infectious disease testing market is experiencing sustained growth driven by the rising burden of infectious diseases including tuberculosis (10.7 million cases), malaria (282 million cases), and dengue (14.6 million cases in 2024. Industry players are pursuing strategic initiatives to expand capabilities, with bioMérieux acquiring Day Zero Diagnostics' assets in June 2025 to enhance NGS capabilities and Sysmex forming a distribution alliance with QIAGEN in Japan. North America holds the largest market share while Asia Pacific emerges as the fastest-growing region, supported by expanding healthcare infrastructure and government investment.The Mass Spectrometry Web PortalDay Zero Diagnostics–Mérieux: investment, 202506 acquisition <$25m of assets of Day Zero Diagnostics by bioMérieuxbioMérieux agreed to acquire Day Zero Diagnostics' assets, including NGS workflows and software, for under $25m. The acquisition aims to enhance next-generation sequencing and rapid diagnostics for infectious diseases. Integration costs will be embedded in bioMérieux's annual R&D investments.openPR.comAI in Radiology Market 18.25% CAGR Outlook Led by Aidoc Medical Ltd AliveCor Arterys Behold Butterfly Network Caption Health Day Zero Diagnostics DiA Imaging Analysis LtdThe AI in radiology market is projected to grow at an 18.25% CAGR from 2025 to 2032, reaching a valuation of about $5 billion. Growth is driven by AI algorithms improving diagnostic accuracy and workflow efficiency, with key players including Aidoc, AliveCor, and GE Healthcare.rapidmicrobiologybioMérieux Acquires Day Zero Diagnostics SolutionsbioMérieux has announced an agreement to acquire the assets of US-based Day Zero Diagnostics, including its technologies for direct-from-whole-blood sample preparation and sequencing. This strategic acquisition aims to enhance bioMérieux's capabilities in next-generation sequencing and rapid diagnostics to combat antibiotic-resistant infections.IdseIDWeek Spotlights New Rapid ID Diagnostics in the PipelinePhAST, deepull, and Day Zero Diagnostics presented new rapid infectious disease diagnostic assays at IDWeek 2024 in Los Angeles to address limitations in current sepsis and bloodstream infection testing. Each company showcased distinct technologies—phenotypic microscopy, multiplex PCR, and whole-genome sequencing—that promise faster turnaround times and improved accuracy for antimicrobial susceptibility testing compared to standard blood cultures.YahooThe cutting edge: five exciting medical device startups to watchFive medical device startups are profiled, including Rubi Life's passive foetal monitor, Livongo's diabetes management system, Day Zero Diagnostics' rapid genomic sequencing, Prellis Biologics' 3D-printed tissues, and Clinical Science Systems' EEG service. Livongo raised $105m, and Day Zero aims to identify bacterial infections within five hours.PR NewswireOxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection DiagnosticsOxford Nanopore and Day Zero Diagnostics announced a collaboration to develop a bloodstream infection diagnostic system that provides same-day organism identification and antibiotic susceptibility profiling without blood culture. The system integrates DZD's AI-driven Keynome pipeline with Oxford Nanopore's PromethION 2 Solo sequencer, targeting clinical hospital labs. The companies plan to pursue FDA regulatory approvals.PR NewswireDay Zero Diagnostics Names Jeff Mirviss Chair of Board of DirectorsDay Zero Diagnostics announced the appointment of Jeff Mirviss as chair of its board of directors, effective immediately. Mirviss brings over 30 years of healthcare experience, currently serving as executive vice president and president of the Peripheral Interventions business at Boston Scientific, and serves on the Executive Board of AdvaMed. The company stated his expertise in strategic investments and corporate transactions will support its approach to commercialization and strategic partnerships.PR NewswireDay Zero Diagnostics to Present AI-Based Antimicrobial Susceptibility Testing Predictive Models at ID WeekDay Zero Diagnostics has been selected to deliver two presentations at the 2023 ID Week conference in Boston, where the company will present results comparing AI-based AST Prediction models against traditional genomic algorithm methods, and showcase its Keynome gAST algorithm for predicting antimicrobial susceptibility from whole-genome sequences. The company is also launching a new commercial service called EpiXact ID, a rapid turnaround service providing high-resolution organism identification using nanopore whole-genome sequencing, expanding its existing lab services portfolio.